In two phase 3 trials (614 adults and adolescents with non-segmental vitiligo), upadacitinib 15 mg daily beat placebo at week 48: T-VASI 50 in 19% and 21% vs 6% and 6%; F-VASI 75 in 25% and 23% vs 6% and 7% (p<0·001). No new safety signals.
RCTn = 614
Passeron et al. Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies